Drug intelligence / Profile preview

CS-8080

Development stage: Phase 1
Lead developer: Daiichi Sankyo
Modality: Small Molecules
Administration: Oral

Overview

CS-8080 is an investigational small molecule drug developed by Daiichi Sankyo. It acts as an agonist of the Liver X receptor (LXR), specifically targeting the LXR-beta isoform, and is being studied for its potential to treat cardiovascular diseases such as atherosclerosis. LXRs are nuclear receptors involved in cholesterol metabolism and inflammation; agonism of these receptors may help reduce atherosclerotic plaque formation and improve lipid profiles. Clinical development has included Phase 1 trials assessing safety, pharmacokinetics, and pharmacodynamics in healthy volunteers[1][2][3][7].

Other names: Liver X receptor modulator (artherosclerosis)LXR modulator (anti-arteriosclerotic)

Targets

NR1H3 (Liver X receptor beta)LXRB (Liver X receptor beta)

Beyond the preview

Go deeper on CS-8080.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CS-8080.

Explore the full profile